REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
Epistemonikos ID: e850fb8db1d5967d40c1ee285bdd4497d0bff9f1
First added on: May 12, 2024